JP6916180B2 - グルコピラノシル誘導体の複合体並びにその調製方法及び使用 - Google Patents

グルコピラノシル誘導体の複合体並びにその調製方法及び使用 Download PDF

Info

Publication number
JP6916180B2
JP6916180B2 JP2018527236A JP2018527236A JP6916180B2 JP 6916180 B2 JP6916180 B2 JP 6916180B2 JP 2018527236 A JP2018527236 A JP 2018527236A JP 2018527236 A JP2018527236 A JP 2018527236A JP 6916180 B2 JP6916180 B2 JP 6916180B2
Authority
JP
Japan
Prior art keywords
inhibitor
complex
mixture
agent
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018527236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535237A5 (enExample
JP2018535237A (ja
Inventor
タン、ペンホ
グ、ツェン
ウ、ウヨン
ツァン、ゾンヤン
カン、パンパン
ク、トン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of JP2018535237A publication Critical patent/JP2018535237A/ja
Publication of JP2018535237A5 publication Critical patent/JP2018535237A5/ja
Application granted granted Critical
Publication of JP6916180B2 publication Critical patent/JP6916180B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2018527236A 2015-11-27 2016-11-28 グルコピラノシル誘導体の複合体並びにその調製方法及び使用 Active JP6916180B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510851466.7 2015-11-27
CN201510851466 2015-11-27
PCT/CN2016/107543 WO2017088839A1 (en) 2015-11-27 2016-11-28 A complex of a glucopyranosyl derivative and preparation method and use thereof

Publications (3)

Publication Number Publication Date
JP2018535237A JP2018535237A (ja) 2018-11-29
JP2018535237A5 JP2018535237A5 (enExample) 2019-11-21
JP6916180B2 true JP6916180B2 (ja) 2021-08-11

Family

ID=58763019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018527236A Active JP6916180B2 (ja) 2015-11-27 2016-11-28 グルコピラノシル誘導体の複合体並びにその調製方法及び使用

Country Status (8)

Country Link
US (1) US10555930B2 (enExample)
EP (1) EP3371199B1 (enExample)
JP (1) JP6916180B2 (enExample)
CN (1) CN106810582B (enExample)
AU (1) AU2016360634B2 (enExample)
CA (1) CA3005920C (enExample)
ES (1) ES3005482T3 (enExample)
WO (1) WO2017088839A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107778336B (zh) * 2016-08-24 2022-09-27 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物的结晶形式
CN108239123B (zh) * 2016-12-27 2021-08-27 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物的共晶、制备方法和应用
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN110407891A (zh) * 2019-07-31 2019-11-05 扬子江药业集团北京海燕药业有限公司 一种sglt-2抑制剂中间体的精制方法
WO2022161377A1 (en) * 2021-01-27 2022-08-04 Sunshine Lake Pharma Co., Ltd. A phamaceutical composition comprising a glucopyranosyl derivative
WO2022204907A1 (en) * 2021-03-30 2022-10-06 Sunshine Lake Pharma Co., Ltd. Method for preparing cocrystal of l-pyroglutamic acid and glucopyranosyl derivative
CN115141235B (zh) * 2021-03-30 2024-08-09 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物的l-焦谷氨酸共晶的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
WO2015027963A1 (zh) 2013-09-02 2015-03-05 四川海思科制药有限公司 芳环类衍生物、其药物组合物及其应用
EP2895490B1 (en) * 2013-09-27 2016-10-19 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses in medicine
WO2016173425A1 (en) * 2015-04-30 2016-11-03 Sunshine Lake Pharma Co., Ltd. A glucopyranosyl derivative and preparation method and uses thereof

Also Published As

Publication number Publication date
AU2016360634A1 (en) 2018-06-07
CN106810582B (zh) 2019-12-31
CA3005920A1 (en) 2017-06-01
US10555930B2 (en) 2020-02-11
CN106810582A (zh) 2017-06-09
HK1254667A1 (en) 2019-07-26
CA3005920C (en) 2023-08-22
AU2016360634B2 (en) 2020-05-21
ES3005482T3 (en) 2025-03-14
EP3371199A1 (en) 2018-09-12
WO2017088839A1 (en) 2017-06-01
EP3371199B1 (en) 2024-12-25
US20180344689A1 (en) 2018-12-06
JP2018535237A (ja) 2018-11-29
EP3371199A4 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
AU2016360634B2 (en) A complex of a glucopyranosyl derivative and preparation method and use thereof
RU2577334C2 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА МОНОГИДРАТА ГИДРОХЛОРИДА (R)-7-ХЛОР-N-(ХИНУКЛИДИН-3-ИЛ)БЕНЗО[b]ТИОФЕН-2-КАРБОКСАМИДА
CN110577534B (zh) 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
WO2022100623A1 (zh) 氮取代杂环噻吩类化合物及其用途
CN108239123B (zh) 吡喃葡萄糖基衍生物的共晶、制备方法和应用
KR20120114174A (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법
CN106674294B (zh) 吡喃葡萄糖基衍生物的结晶形式
CN107778336B (zh) 吡喃葡萄糖基衍生物的结晶形式
JP6972390B2 (ja) Ｃｄｋ４／６キナーゼ阻害剤を標的とする結晶形
CN104817554A (zh) 一类葡萄糖苷衍生物及其药物组合物
WO2021143819A1 (zh) 多环类间变性淋巴瘤激酶抑制剂的晶型
US9550732B2 (en) Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof
EP4635947A2 (en) Crystal form of glucopyranosyl derivative and use thereof
TW202102487A (zh) N-(5-((4-乙基哌𠯤-1-基)甲基)吡啶-2-基)-5-氟-4-(3-異丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其鹽的結晶與非晶型以及其製備方法與醫療用途
TWI410425B (zh) 唑并［５，４－ｂ］吡啶－５－基化合物
HK1254667B (en) A complex of a glucopyranosyl derivative and preparation method and use thereof
US20250074892A1 (en) Carbonyl bridged heterocyclic compound, and composition and application thereof
JP6574843B2 (ja) 化合物のａ結晶形およびその製造方法
CN118206518A (zh) 吡喃葡萄糖基衍生物的共晶及其用途
CN118206517A (zh) 吡喃葡萄糖基衍生物的共晶及其用途
CN118206516A (zh) 吡喃葡萄糖基衍生物的共晶及其用途
TW202604493A (zh) Ripk2抑制劑之晶型

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191011

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191107

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20201106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210621

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210715

R150 Certificate of patent or registration of utility model

Ref document number: 6916180

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250